Group 1 - BeOne Medicines Ltd. reported $1.32 billion in revenue for the quarter ended June 2025, a year-over-year increase of 41.6% [1] - The earnings per share (EPS) for the same period was $0.84, compared to -$1.15 a year ago, indicating a significant turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $1.24 billion by 6.17%, and the EPS surprise was 75% above the consensus estimate of $0.48 [1] Group 2 - Key product revenue included BRUKINSA at $949.84 million, TEVIMBRA at $193.52 million, and total product revenue net at $1.3 billion, all surpassing analyst estimates [4] - Collaboration revenue reached $13.22 million, a 64.9% increase compared to the year-ago quarter, exceeding the average estimate of $7.59 million [4] - Other notable product revenues included KYPROLIS at $19.42 million, BLINCYTO at $25.59 million, and XGEVA at $81.32 million, all of which met or exceeded analyst expectations [4] Group 3 - BeOne Medicines Ltd. shares have returned +25.7% over the past month, significantly outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - BeiGene, Ltd. reported $1.12 billion in revenue for Q1 2025, marking a 48.6% year-over-year increase and an EPS of $1.22 compared to -$2.41 a year ago [1] - The revenue matched the Zacks Consensus Estimate of $1.12 billion, resulting in a slight surprise of -0.65%, while the EPS exceeded expectations with a surprise of +271.83% [1] Financial Performance - Product revenue totaled $1.11 billion, slightly below the estimated $1.12 billion by analysts [4] - Key product revenues included: - BRUKINSA (Zanubrutinib): $791.66 million vs. $820.07 million estimated - Tislelizumab: $171.16 million vs. $171.33 million estimated - XGEVA: $70.42 million vs. $56.55 million estimated - Other: $17.90 million vs. $14.28 million estimated - POBEVCY: $13.75 million vs. $16.11 million estimated - BLINCYTO: $23.91 million vs. $20.42 million estimated - KYPROLIS: $19.73 million vs. $16.51 million estimated - Collaboration revenue was $8.75 million, exceeding the $6.49 million estimate [4] Market Performance - BeiGene's shares have returned +15.4% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]